Home » Stocks » GBIO

Generation Bio Co. (GBIO)

Stock Price: $21.10 USD -0.48 (-2.22%)
Updated Jul 29, 2021 4:00 PM EDT - Market closed
Market Cap 1.22B
Revenue (ttm) n/a
Net Income (ttm) -88.37M
Shares Out 56.63M
EPS (ttm) -2.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $21.10
Previous Close $21.58
Change ($) -0.48
Change (%) -2.22%
Day's Open 21.77
Day's Range 20.94 - 22.28
Day's Volume 276,372
52-Week Range 18.80 - 55.72

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Company to transition all portfolio programs to rapid enzymatic synthesis (RES), enabling improved quality, scale and speed of closed-ended DNA manufacturing

2 weeks ago - GlobeNewsWire

CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff ...

3 weeks ago - GlobeNewsWire

CAMBRIDGE, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff ...

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff M...

2 months ago - GlobeNewsWire

Durable, therapeutically relevant levels of anti-SARS-CoV-2 spike antibodies produced from the liver in a mouse model

2 months ago - GlobeNewsWire

CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, today announced three digi...

3 months ago - GlobeNewsWire

CAMBRIDGE, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff...

3 months ago - GlobeNewsWire

$262.3 million cash balance at the end of 2020 bolstered by additional net proceeds of $211.3 million from follow-on offering, funding key milestones into 2024

4 months ago - GlobeNewsWire

Generation Bio (GBIO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

4 months ago - Zacks Investment Research

With the trading day more than halfway over, the broad markets have pushed higher, seemingly recovering from Tuesday.

Other stocks mentioned: ANF, MAT, WDC, ALLK, EBS, EOLS, RDUS ...
5 months ago - 24/7 Wall Street

CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, announced today that Ron Cooper has b...

5 months ago - GlobeNewsWire

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider buying can b...

Other stocks mentioned: CAG, ALDX, DMTK, FATE, MRSN, ORI, REVG ...
6 months ago - Benzinga

CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the closing of its pu...

6 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the pricing of a publ...

6 months ago - GlobeNewsWire

Generation Bio (GBIO) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

6 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that the co...

6 months ago - GlobeNewsWire

Data confirm delivery of closed-ended DNA to the liver via novel, cell-targeted lipid nanoparticles

6 months ago - GlobeNewsWire

The unicorn IPO parade is set to begin in the week ahead, with DoorDash and Airbnb leading the way. A total of six IPOs and two SPACs are scheduled to raise $7.2 billion.

Other stocks mentioned: ABNB, AI, AZEK, DASH, PCVX, RNA, UCL ...
7 months ago - Seeking Alpha

On Track to Advance Lead Programs into Pre-Clinical Development in 2021 Supported by Key Leadership Team Appointments On Track to Advance Lead Programs into Pre-Clinical Development in 2021 Supported by...

8 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Philli...

9 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geo...

10 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Generation Bio Co . (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, today reported recent b...

11 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Generation Bio Co . (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, today announced that ma...

11 months ago - GlobeNewsWire

CAMBRIDGE, Mass., July 22, 2020 (GLOBE NEWSWIRE) -- Generation Bio Co . (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, today announced that Ma...

1 year ago - GlobeNewsWire

CAMBRIDGE, Mass., June 16, 2020 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the closing of its ...

1 year ago - GlobeNewsWire

Shares of Generation Bio Inc., a biotech that specializes in gene therapy treatments for rare diseases, soared 23% Friday in their trading debut, after the IPO was upsized and priced at $19 a share, the...

1 year ago - Market Watch

Generation Bio Inc., a biotech that specializes in gene therapy treatments for rare diseases, priced its upsized initial public offering at $19 a share, the high end of its price range.

1 year ago - Market Watch

CAMBRIDGE, Mass., June 11, 2020 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the pricing of its ...

1 year ago - GlobeNewsWire

About GBIO

Generation Bio Co., a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Industry
Biotechnology
IPO Date
Jun 12, 2020
Stock Exchange
NASDAQ
Ticker Symbol
GBIO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Generation Bio stock is "Strong Buy." The 12-month stock price forecast is 42.50, which is an increase of 101.42% from the latest price.

Price Target
$42.50
(101.42% upside)
Analyst Consensus: Strong Buy